Results 121 to 130 of about 9,895 (222)

Evaluating Thiram‐Induced Embryotoxicity Using Integrated In Silico, In Vitro, and Transcriptomic Approaches

Environmental Toxicology, EarlyView.
ABSTRACT Long‐term exposure to low‐dose food contact materials (FCMs) has raised concerns regarding developmental toxicity. In the present study, we prioritized FCMs with potential developmental toxicity using a weight‐of‐evidence computational model, which predicted 127 chemicals to be of high concern.
Chia‐Chi Ho, Chun‐Wei Tung, B. Linju Yen, Chen‐Yi Weng, Ju‐Hsin Hsu, Ming‐Hsien Tsai, Salim Arrokhman, Pinpin Lin   +7 more
wiley   +1 more source

Effect of PCBs on the lactational transfer of methyl mercury in mice: PBPK modeling [PDF]

, 2009
MeHg and PCB exposure to lactating mice were analyzed and a physiologically based pharmacokinetic (PBPK) model was developed to describe the lactational transfer of MeHg in mice.
Lee, Sun Ku, Lohitnavy, Manupat, Hamer, Dwayne, Yang, Raymond S. H., Bedwell, Cathy L.   +4 more
core   +1 more source

Microplastics and the Endocrine–Metabolic Interface: Novel Diagnostic Tools Targeting Thyroid–Adipose Axis

Environmental Toxicology, EarlyView.
ABSTRACT Microplastics (MPs) have been identified as major environmental contaminants that can affect organisms directly and act as carriers of particles and chemical additives, thereby aggravating endocrine networks that coordinate metabolic homeostasis.
Sunday Amos Onikanni, Babasola Aiyeku, Marjorie Dardis Murucci, Temitope Aribigbola, Kenia Bispo, Oluwatosin Stella Olayinka, Rômulo Sperduto Dezonne, Sara Gemini Piperni, Paula Soares, Denise Pires de Carvalho, Leandro Miranda‐Alves   +10 more
wiley   +1 more source

Evaluation of Luteolin Nanosuspensions on Pharmacokinetics of Atorvastatin: Drug-Drug Interactions Using Rat Models

International Journal of Nanomedicine
You Liang,* Bo Sun,* Min Yang, Xiaona Meng, Meng Wang, Lijuan Yang, Bandar AI-Hamyari, Yuqian Zhang, Yutong Shen, Shengnan Meng Department of Pharmaceutics, School of Pharmacy, China Medical University, Shenyang, 110122, People’s Republic of ...
Liang Y, Sun B, Yang M, Meng X, Wang M, Yang L, AI-Hamyari B, Zhang Y, Shen Y, Meng S   +9 more
doaj  

Predicting Drug Transfer Into Human Milk With the Simcyp Simulator: A Contribution From the ConcePTION Project

CPT: Pharmacometrics & Systems Pharmacology
Physiologically‐based pharmacokinetic (PBPK) modeling can support decision‐making on maternal medication use during breastfeeding. This study aimed to enhance lactation PBPK models in two ways.
Julia Macente, Nina Nauwelaerts, Justine Marine Badée, Rodolfo Hernandes Bonan, Miao‐Chan Huang, Martje Van Neste, Anne Smits, Karel Allegaert, Hedvig Nordeng, Markus Hovd, Frederico Severino Martins, Pieter Annaert   +11 more
doaj   +1 more source

Identification of drug repurposing candidates for the treatment of polycystic kidney disease

British Journal of Pharmacology, EarlyView.
Background and Purpose Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end‐stage renal disease with limited treatment options. Drug repurposing offers a promising strategy to find effective treatments. Experimental Approach We identified birinapant, bardoxolone methyl and salicylic acid as repurposing candidates for ADPKD and
Alina Meyer, Paraskevi Sotiropoulou, Koussai Bouker, Dennis Svedberg, Rebekkah Hammar, Hester Bange, Per Larsson, André Mateus, Daniel R. Dietrich, Per Artursson   +9 more
wiley   +1 more source

Développement de modèle PBPK pour l'optimisation de nanomédicaments [PDF]

Embargo jusqu'au 12/11/2025Nanoparticles (NPs) are promising platforms for targeted drug delivery and improved diagnosis thanks to their unique physicochemical, biological and pharmacokinetic (PK) properties.
Ou, Jessica
core   +2 more sources

In silico prediction of novel effective combinational treatment of chronic pain in individual patients: A joint white paper of the H2020 QSPainRelief consortium

British Journal of Pharmacology, EarlyView.
Abstract Opioids are prescribed widely for chronic pain despite well‐recognised risks and variable long‐term benefit, reflecting the lack of effective alternatives for many patients. Combination therapies offer a promising strategy to enhance efficacy whilst reducing side effects.
André Mouraux, Solenn Gousset, Beltrán Alvarez, Monica Baiula, Wouter Bakker, Andrea Bedini, Monir Bertayli, Divakar Budda, Robert Carr, Elisabetta Cuna, Óscar Díaz, Nina Donner, Jesús Giraldo, Geert‐Jan Groeneveld, Berfin Gülave, David Guydan, Hemme Hijma, Rafael Maldonado, Pedro Renault, Carlos Rinaudo, Jeroen Elaissaiss‐Schaap, Athan Spiros, Sara Stoeber, Petri Takkala, Daan van Valkengoed, Coen van Hasselt, Elizabeth (Liesbeth) CM de Lange   +26 more
wiley   +1 more source

Exploring inter-ethnic and inter-patient variability and optimal dosing of osimertinib: a physiologically based pharmacokinetic modeling approach

Frontiers in Pharmacology
Purpose: This study aimed to develop and validate a physiologically based pharmacokinetic (PBPK) model for osimertinib (OSI) to predict plasma trough concentration (Ctrough) and pulmonary EGFRm+ (T790M and L858R mutants) inhibition in Caucasian, Japanese,
Feng Liang, Yimei Zhang, Qian Xue, Na Yao   +3 more
doaj   +1 more source

Beyond Tradition: An Integrated Toxicological, Ecological, and Public Health Perspective on Aristolochic Acids

Journal of Applied Toxicology, Volume 46, Issue 8, Page 2599-2622, August 2026.
ABSTRACT Aristolochia species have long been used in traditional medicine for their presumed anti‐inflammatory, analgesic and antimicrobial properties. However, extensive toxicological and epidemiological evidence now demonstrates that these plants contain aristolochic acids (AAs) I and II, highly potent nephrotoxic, genotoxic, and carcinogenic ...
Victor Ventura de Souza, Lara Rodrigues De Andrade, Tatiana da Silva Souza   +2 more
wiley   +1 more source